Virus that kills cancer.

[Drphil1938]

Here is a link to a very interesting article that I would like for all of you to read and comment. If true, it is very exciting and could save many lives. However, I am skeptical that something this groundbreaking would be sitting in a freezer because of the lack of a few million dollars. I would be very interested in some of the comments from many of our very learned members. Please read:

telegraph.co.uk/news/scienc...

[Fairwind]

Something like this would be worth a $trillion$ dollars to a big pharma company..Saving lives is not the top priority. Making money for shareholders is the top priority..Since the virus is common and probably not patentable, the backstage maneuvering for position, clinical trials, production rights, all that stuff must be settled first. If it really works...One should note there have been dozens of false alarms like this that just don't pan out...

[Drphil1938 in reply to Fairwind]

Skeptical but hopeful. It did sound like Dr.khell may begin private patient trials in the near future.

[pjoshea13]

That was written in 2012.

This is Essand's most recent paper (searching on "Neuroendocrine"):

ncbi.nlm.nih.gov/pubmed/274...

Neuroendocrinology. 2017;105(1):54-66. doi: 10.1159/000448430. Epub 2016 Jul 21.

Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer.

Yu D1, Leja-Jarblad J, Loskog A, Hellman P, Giandomenico V, Oberg K, Essand M.

Author information

Abstract

Cancer immunotherapy is becoming a cornerstone in the clinical care of cancer patients due to the breakthrough trials with immune checkpoint blockade antibodies and chimeric antigen receptor T cells. The next breakthrough in cancer immunotherapy is likely to be oncolytic viruses engineered to selectively kill tumor cells and deceive the immune system to believe that the tumor is a foreign entity that needs to be eradicated. We have developed AdVince, an oncolytic adenovirus for treatment of liver metastases from neuroendocrine tumor (NET). AdVince includes the gene promoter from human chromogranin A for selective replication in neuroendocrine cells, miR122 target sequences for reduced liver toxicity, and a cell-penetrating peptide in the capsid for increased infectivity of tumor cells and optimized spread within tumors. This paper describes the preclinical evaluation of AdVince on freshly isolated human gastrointestinal NET cells resected from liver metastases and freshly isolated human hepatocytes as well as in fresh human blood. AdVince selectively replicates in and kills NET cells. Approximately 73-fold higher concentration of AdVince is needed to induce a similar level of cytotoxicity in NET cells as in hepatocytes. AdVince did not activate complement or induce considerable amount of proinflammatory cytokines or chemokines in human blood. The data presented herein indicate that AdVince can be safely evaluated in a phase I/IIa clinical trial for patients with liver-dominant NET.

© 2016 S. Karger AG, Basel.

KEYWORDS:

AdVince; Immunotherapy; Liver metastases; Neuroendocrine cancer; Oncolytic adenovirus

PMID: 27442441 DOI: 10.1159/000448430

[Indexed for MEDLINE]

-Patrick

[Drphil1938 in reply to pjoshea13]

I did not look at written date, it was in the July 1, 2019 edition of the Telegraph so I assumed it was current. Thanks for pointing out, sorry, never assume because you know. But still curious about this research.

[Bjry in reply to Drphil1938]

A different press story but similar date.

smh.com.au/technology/could...

This line of research started in the USA with William Coley in about 1890! But the research was killed by those who thought chemotherapy and radiation were the way to go. Worth researching Coley's contribution - its a good story.

[pjoshea13 in reply to Drphil1938]

No need for apologies. I usually check dates of newspaper studies. The Daily Mail must have reported that Robert de Niro has PCa at least 5 times this year. It was news in 2003.

-Patrick

[j-o-h-n in reply to pjoshea13]

He does? You talking to me?

Good Luck, Good Health and Good Humor.

j-o-h-n Saturday 07/06/2019 7:32 PM DST

[Hidden]

The only active Virus "cure" I know of that is ongoing is the Riga Virus (Rigvir). At a price, you go to Riga (in Latvia) and book into their clinic, and they infect you with the Riga virus. It all sounds good (and it may be good), but when I asked them for case studies and their results with Pca they went silent. You can read about them on the Internet. Until they come clean with real results to look at, it will be (for me), yet another scheme to make money using some morsel of truth.

That said, the principle of using a virus as a Trojan Horse could well become a winner one day. Today's news had a piece that the common cold virus kills bladder cancer.

[Bjry]

Not new: a summary of virus treatment clinical trials (including for prostate cancer) as at 2017.

onlinelibrary.wiley.com/doi...

[AlanLawrenson]

I looked closely at the Riga outfit in 2014 when I was writing my first PCa book (an ABC of Prostate Cancer in 2015). I also obtained feedback from the Hope4Cancer Clinic in Tijuana, just over the Mexican border from San Diego. After some months of 'trials' they discontinued RigVir. At the time they gave me good technical feedback as to why it didn't work on most PCa men.

By the way, I'm well advanced in writing a 3rd edition of my 2016 book An ABC of Prostate Cancer Today. It includes a "Future Developments" chapter that looks at about 20 technologies that presently are in trials or will do so in the next year. Some very exciting developments that might change PCa therapies by 2021 or thereabouts.

[Drphil1938 in reply to AlanLawrenson]

Thanks, let us know when you publish it.

[Scout4answers in reply to AlanLawrenson]

Are any of these new therapies showing any promise?

[AlanLawrenson in reply to Scout4answers]

Hi Scout,

An interesting question that you raise. In my latest book "An ABC of Prostate Cancer Today - 3rd Edition", Chapter 22 Future Developments features about 20 technologies that showed promise in treating PCa. Researching and writing this book, which was 'launched' in the early days of COVID and as a result sold in the high hundreds, rather than its earlier versions sold in the thousands, pretty well exhausted me. I also lost my brother to PCa in January 20, which also motivated me to be 'up' with all possible therapies that might have helped him.

I will look in depth at this Chapter down the track, but I can say that I am 'invested' in at least three of the therapies included. By 'invested' I mean I hold stock in companies active in these areas. The three are:

Veyonda : I am still of the view that it will become a mainstream therapy for PCa within 3 years. Clinical trials are progressing well, but they will another 2 years to conclude.

Dendrimer: Same story, but PCa is only of medium interest.

CAR-T: There are dozens of companies active in this space. Some treatments (not PCa) have lead to 'cures'. Others are in trials (various stages). Prescient Therapeutics (ASX: PTX) are advancing CAR-T with seven different approaches. Some are combining CAR-T with NK cells. CAR-T will become a main stream therapy for many cancers, including PCa down the track.

I hope this is of interest.

My books are still available on Amazon (print and eBook).

[Bjry]

Not all newspaper cancer reports are total beat ups:

from ecancer.org/news/

"05 Jul 2019

A strain of the common cold virus has been found to potentially target, infect and destroy cancer cells in patients with bladder cancer, a new study in the medical journal Clinical Cancer Research reports. "